Germany mandates real-world data collection for gene therapy Zolgensma
Germany’s HTA body is telling Novartis exactly what post-approval efficacy data it needs to see for SMA therapy Zolgensma.
top of page
Never miss an update, subscribe today.
RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.
bottom of page